Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.
Matsuoka H, Arao T, Makimura C, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Tanigawara Y, Yamanaka T, Tanaka K, Nishio K, Nakagawa K. Matsuoka H, et al. Among authors: kiyota h. Oncol Rep. 2012 May;27(5):1393-9. doi: 10.3892/or.2012.1660. Epub 2012 Jan 26. Oncol Rep. 2012. PMID: 22293824
Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.
Okamoto I, Takeda K, Daga H, Miyazaki M, Yonesaka K, Kiyota H, Tsurutani J, Ueda S, Ichikawa Y, Takeda M, Sekiguchi R, Tominaga K, Enatsu S, Nambu Y, Nakagawa K. Okamoto I, et al. Among authors: kiyota h. Lung Cancer. 2010 Nov;70(2):168-73. doi: 10.1016/j.lungcan.2010.02.007. Epub 2010 Mar 16. Lung Cancer. 2010. PMID: 20236726
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K. Kidera Y, et al. Among authors: kiyota h. Int J Clin Oncol. 2011 Jun;16(3):244-9. doi: 10.1007/s10147-010-0170-6. Epub 2011 Jan 18. Int J Clin Oncol. 2011. PMID: 21243395
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Murakami H, Kurata T, Onozawa Y, Watanabe J, Ono A, Takahashi T, Yamamoto N, Fujisaka Y, Kiyota H, Hayashi H, Tanaka K, Nakagawa K, Kuroda S. Murakami H, et al. Among authors: kiyota h. Cancer Chemother Pharmacol. 2014 Mar;73(3):623-30. doi: 10.1007/s00280-014-2388-x. Epub 2014 Jan 30. Cancer Chemother Pharmacol. 2014. PMID: 24477603 Free PMC article. Clinical Trial.
Significance of targeted antimicrobial prophylaxis using rectal-culture selective screening media prior to transrectal prostate biopsy: A multicenter, randomized controlled trial.
Sadahira T, Sekito T, Maruyama Y, Ichikawa T, Kurihara Y, Shiraishi H, Sakuma T, Tokunaga M, Mitsui Y, Kusumi N, Tominaga Y, Katayama S, Iwata T, Nishimura S, Edamura K, Kobayashi T, Watanabe M, Hiyama Y, Yamada H, Kurata H, Kondo T, Mitsui M, Takenaka T, Kiyota H, Araki M, Miyazaki J, Takahashi S, Yamamoto S, Wada K. Sadahira T, et al. Among authors: kiyota h. Urology. 2024 Dec 16:S0090-4295(24)01144-0. doi: 10.1016/j.urology.2024.12.018. Online ahead of print. Urology. 2024. PMID: 39694101
247 results